Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1

Conditions

Hematologic Neoplasms 2Multiple Myeloma 1

Interventions

Cytarabine 10venetoclax 8Rituximab 7Daunorubicin 7nilotinib 6Azacitidine 6blinatumomab 5Bendamustine Hydrochloride 5bosutinib 4Imatinib Mesylate 4obinutuzumab 3asciminib 3acalabrutinib 3Mitoxantrone 3Methotrexate 3Etoposide 3Dexamethasone 3Decitabine 3Dasatinib 3zanubrutinib 2trametinib 2talquetamab 2revumenib 2pirtobrutinib 2pegaspargase 2ivosidenib 2idelalisib 2ibrutinib 2fludarabine 2decitabine and cedazuridine drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × talquetamab × Other hematologic neoplasm × Clear all
NCT03399799 2026-05-08

MonumenTAL-1

Janssen Research & Development, LLC

Phase 1 Active not recruiting
279 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT04634552 2026-05-08

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡